Differential action of anti-emetic drugs on defecation and emesis induced by prostaglandin E2 in the ferret

European Journal of Pharmacology

Volumn 544, Issue 1-3, 2006, Pages 153-159

  Kan, Kelvin K W ^a   Rudd, John A ^a   Wai, Man K ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (China)

Author keywords

Defecation; Emesis; Ferret; Prostanoid

Indexed keywords

3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTIEMETIC AGENT; DOMPERIDONE; DROPERIDOL; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PROSTAGLANDIN E2; SCOPOLAMINE; SEROTONIN 3 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEFECATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FERRET; MALE; NONHUMAN; PRIORITY JOURNAL; TENESMUS; TREATMENT FAILURE; VAGOTOMY; VOMITING;

EID: 33746583107     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.034     Document Type: Article

References (48)

1. Andrews P.L.R., and Rudd J.A. The role of tachykinins and the tachykinin receptor in nausea and emesis. In: Holzer P. (Ed). Handbook of Experimental Pharmacology vol. 164 (2004), Springer-Verlag Berlin Heidelberg, Berlin, Germany 359-440
2. Andrews P.L.R., Davis C.J., Bingham S., Davidson H.I.M., Hawthorn J., and Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can. J. Physiol. Pharmacol. 68 (1990) 325-345
3. Bhandari P., Bingham S., and Andrews P.L. The neuropharmacology of loperamide-induced emesis in the ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology 31 (1992) 735-742
4. Bianchi Porro G., and Parente F. Side effects of anti-ulcer prostaglandins: an overview of the worldwide clinical experience. Scand. J. Gastroenterol. 164 Suppl. 224-229 (1989) 229-231
5. Bountra C., Bunce K., Dale T., Gardner C., Jordan C., Twissell D., and Ward P. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur. J. Pharmacol. 249 (1993) R3-R4
6. Briggs D.B., and Carpenter D.O. Excitation of neurons in the canine area postrema by prostaglandins. Cell. Mol. Neurobiol. 6 (1986) 421-426
7. Butler A., Hill J.M., Ireland S.J., Jordan C.C., and Tyers M.B. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br. J. Pharmacol. 94 (1988) 397-415
8. Coleman R.A., Smith W.L., and Narumiya S. International Union of Pharmacology. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46 (1994) 205-229
9. Costa M., and Furness J.B. The peristaltic reflex: an analysis of the nerve pathways and their pharmacology. Naunyn-Schmiedebergs Arch. Pharmacol. 294 (1976) 47-60
10. Dahlof C.G., and Hargreaves R.J. Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies?. Cephalalgia 18 (1998) 593-604
11. De Saedeleer V., Wechsung E., and Houvenaghel A. Effect of infusion of a diarrheogenic dose of PGE2 on gastrointestinal electrical activity in the conscious piglet. Prostaglandins Leukot. Essent. Fat. Acids 15 Suppl. 3 (1992) 43-49
12. Fahmy K. Prophylaxis against prostaglandin-induced gastrointestinal side effects. Int. J. Gynaecol. Obstet. 19 (1981) 487-489
13. Froehlich J.M., Patak M.A., von Weymarn C., Juli C.F., Zollikofer C.L., and Wentz K.U. Small bowel motility assessment with magnetic resonance imaging. J. Magn. Reson. Imaging 21 (2005) 370-375
14. Fukuda H., and Koga T. The Botzinger complex as the pattern generator for retching and vomiting in the dog. Neurosci. Res. 12 (1991) 471-485
15. Girod V., Bouvier M., and Grelot L. Characterization of lipopolysaccharide-induced emesis in conscious piglets: effects of cervical vagotomy, cyclooxygenase inhibitors and a 5-HT(3) receptor antagonist. Neuropharmacology 39 (2000) 2329-2335
16. Gore S., Gilmore I.T., Haigh C.G., and Brownless S.M. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment. Pharmacol. Ther. 4 (1990) 139-144
17. Goyal R.K., and Hirano I. The enteric nervous system. New Eng. J. Med. 334 (1996) 1106-1115
18. Grant S.M., and Goa K.L. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43 (1992) 889-924
19. Hamik A., and Peroutka S.J. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother. Pharmacol. 24 (1989) 307-310
20. Higgins G.A., Kilpatrick G.J., Bunce K.T., Jones B.J., and Tyres M.B. 5-HT3 Receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br. J. Pharmacol. 97 (1989) 247-255
21. Jin J.G., Foxx O.A.E., and Grider J.R. Propulsion in the guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J. Pharmacol. Exp. Ther. 288 (1999) 93-97
22. Kamato T., Ito H., Nagakura Y., Nishida A., Yuki H., Yamano M., and Miyata K. Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets. Eur. J. Pharmacol. 238 (1993) 369-376
23. Kan K.K.W., Jones R.L., Ngan M.P., and Rudd J.A. Actions of prostanoids to Induce emesis and defecation in the ferret. Eur. J. Pharmacol. 453 (2002) 299-308
24. Kan K.K.W., Jones R.L., Ngan M.P., Rudd J.A., and Wai M.K. Emetic action of the TP prostanoid receptor agonist, U46619, in Suncus murinus (the House Musk Shrew). Eur. J. Pharmacol. 482 (2003) 297-304
25. Kan K.K.W., Jones R.L., Ngan M.P., and Rudd J.A. Excitatory action of prostanoids on the ferret isolated vagus nerve preparation. Eur. J. Pharmacol. 491 (2004) 37-47
26. Karim S.M., and Adaikan P.G. The effect of loperamide on prostaglandin induced diarrhoea in rat and man. Prostaglandins 13 (1977) 321-331
27. Lange A.P., Secher N.J., and Amery W. Prostaglandin-induced diarrhoea treated with loperamide or diphenoxylate. A double-blind study. Acta Med. Scand. 202 (1977) 449-454
28. Lauersen N.H., and Wilson K.H. The effects of intramuscular injections of 15(S)-15-methyl prostaglandin F2alpha in failed abortions. Fertil. Steril. 28 (1977) 1044-1047
29. Lippes J., and Hurd M. The use of chlorpromazine and lomotil to prevent and/or reduce the side effects of prostaglandin E2 used for abortion. Contraception 12 (1975) 569-577
30. Mach T. The brain-gut axis in irritable bowel syndrome-clinical aspects. Med. Sci. Monit. 10 (2004) RA125-RA131
31. Montastruc J.L., Llau M.E., Rascol O., and Senard J.M. Drug-induced parkinsonism: a review. Fundam. Clin. Pharmacol. 8 (1994) 293-306
32. Nagakura Y., Kiso T., Miyata K., Ito H., Iwaoka K., and Yamaguchi T. The effect of the selective 5-HT3 receptor agonist on ferret gut motility. Life Sci. 71 (2002) 1313-1319
33. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79 (1999) 1193-1226
34. Negishi M., Sugimoto Y., and Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim. Biophys. Acta 1259 (1995) 109-119
35. Nelson G.H., and Bryans Jr. C.I. A comparison of oral prostaglandin E2 and intravenous oxytocin for induction of labor in normal and high-risk pregnancies. Am. J. Obstet. Gynecol. 126 (1976) 549-554
36. Niemegeers C.J. Antiemetic specificity of dopamine antagonists. Psychopharmacology 78 (1982) 210-213
37. Ozaki A., Yoshidomi M., and Sukamoto T. Effect of the 5-hydroxytryptamine3 (5-HT3)-receptor antagonist KB-R6933 on experimental diarrhea models. Jpn. J. Pharmacol. 80 (1999) 93-96
38. Qin X.Y., Pilot M.A., Thompson H., and Scott M. Effects of cholinoceptor and 5-Hydroxytryptamine(3)-receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis. Br. J. Pharmacol. 108 (1993) 44-49
39. Reiter M., Bucek R.A., Stumpflen A., Dirisamer A., and Minar E. Prostanoids in the treatment of intermittent claudication-a meta-analysis. Vasa 31 (2002) 219-224
40. Rudd J.A., Bunce K.T., and Naylor R.J. The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology 35 (1996) 91-97
41. Rupniak N.M., and Kramer M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 20 (1999) 485-490
42. Sato T., Hirota K., Matsuki A., Zsigmond E.K., and Rabito S.F. Droperidol inhibits tracheal contraction induced by serotonin, histamine or carbachol in guinea pigs. Can. J. Anaesth. 43 (1996) 172-178
43. Schaff E.A., Eisinger S.H., Franks P., and Kim S.S. Combined methotrexate and misoprostol for early induced abortion. Arch. Fam. Med. 4 (1995) 774-779
44. Smith R.N. Safety of ondansetron. Eur. J. Cancer Clin. Oncol. 25 Suppl. 1 (1989) S47-S50
45. Stewart J.J., Wood M.J., Wood C.D., and Mims M.E. Effects of motion sickness and antimotion sickness drugs on gastric function. J. Clin. Pharmacol. 34 (1994) 635-643
46. Swanson B.N. Medical use of dimethyl sulfoxide (DMSO). Rev. Clin. Basic Pharmacol. 5 (1985) 1-33
47. Thavarasah A.S., and Almohdzar S.A. Prostaglandin (F2 alpha) in missed abortion. Intravenous, extra-amniotic and intramuscular administration-a randomized study. Biol. Res. Pregnancy Perinatol. 7 (1986) 106-110
48. Zavecz J.H., Jackson T.E., Limp G.L., and Yellin T.O. Relationship between anti-diarrheal activity and binding to calmodulin. Eur. J. Pharmacol. 78 (1982) 375-377